Aravive (NASDAQ:ARAV) PT Raised to $12.00

Aravive (NASDAQ:ARAV – Get Rating) had its price objective upped by equities research analysts at HC Wainwright from $7.00 to $12.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage currently has a “buy” rating on the stock.

Separately, EF Hutton Acquisition Co. I restated a “buy” rating and issued a $10.00 target price on shares of Aravive in a report on Tuesday, February 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $9.20.

Aravive Trading Up 13.7 %

Shares of Aravive stock opened at $1.83 on Wednesday. The company has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $1.40. Aravive has a 12-month low of $0.58 and a 12-month high of $2.23. The stock has a market cap of $109.49 million, a price-to-earnings ratio of -0.78 and a beta of 2.35.

Institutional Trading of Aravive

A number of large investors have recently bought and sold shares of ARAV. Artal Group S.A. raised its position in Aravive by 248.7% during the 4th quarter. Artal Group S.A. now owns 4,572,515 shares of the company’s stock worth $6,036,000 after buying an additional 3,261,224 shares during the last quarter. Two Sigma Investments LP purchased a new position in Aravive during the 4th quarter worth $167,000. Renaissance Technologies LLC raised its position in Aravive by 35.0% during the 2nd quarter. Renaissance Technologies LLC now owns 374,945 shares of the company’s stock worth $370,000 after buying an additional 97,116 shares during the last quarter. Millennium Management LLC raised its position in Aravive by 58.9% during the 2nd quarter. Millennium Management LLC now owns 96,838 shares of the company’s stock worth $96,000 after buying an additional 35,900 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Aravive by 271.9% during the 4th quarter. Jane Street Group LLC now owns 42,115 shares of the company’s stock worth $56,000 after buying an additional 30,792 shares during the last quarter. Institutional investors and hedge funds own 16.85% of the company’s stock.

About Aravive

(Get Rating)

Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.